TVTX · Forms 3, 4, 5
Insider trades at Travere Therapeutics, Inc.
1 insider sold $13.1M of Travere Therapeutics, Inc. stock on the open market in the last 30 days.
Every Form 3, 4 and 5 filed for Travere Therapeutics, Inc. (TVTX) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Insider trades in the last 90 days
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Option exercise | 43,735 | $26.88 | $1.2M | Form 4 | |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Option exercise | 200,000 | $8.93 | $1.8M | Form 4 | |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Sell (10b5-1 plan) | 128,065 | $52.97 | $6.8M | Form 4 | |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Sell (10b5-1 plan) | 37,270 | $54.20 | $2M | Form 4 | |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Sell (10b5-1 plan) | 78,400 | $55.02 | $4.3M | Form 4 | |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Option exercise | 8,282 | $22.40 | $186K | Form 4 | |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Sell (10b5-1 plan) | 8,282 | $65.07 | $539K | Form 4 | |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Option exercise | 108,493 | $23.34 | $2.5M | Form 4 | |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Sell (10b5-1 plan) | 101,691 | $64.59 | $6.6M | Form 4 | |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Sell (10b5-1 plan) | 6,802 | $64.95 | $442K | Form 4 | |
| William E. Rote | Chief Research Officer | Option exercise | 350 | $17.96 | $6K | Form 4 | |
| William E. Rote | Chief Research Officer | Option exercise | 55,000 | $15.46 | $850K | Form 4 | |
| William E. Rote | Chief Research Officer | Option exercise | 57,500 | $26.88 | $1.5M | Form 4 | |
| William E. Rote | Chief Research Officer | Sell (10b5-1 plan) | 65,104 | $63.12 | $4.1M | Form 4 | |
| William E. Rote | Chief Research Officer | Sell (10b5-1 plan) | 47,746 | $63.61 | $3M | Form 4 | |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Option exercise | 100,000 | $11.25 | $1.1M | Form 4 | |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Option exercise | 55,000 | $15.46 | $850K | Form 4 | |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Option exercise | 17,717 | $26.88 | $476K | Form 4 | |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Sell (10b5-1 plan) | 93,604 | $63.25 | $5.9M | Form 4 | |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Sell (10b5-1 plan) | 79,113 | $63.65 | $5M | Form 4 | |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Option exercise | 195,841 | $23.34 | $4.6M | Form 4 | |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Sell (10b5-1 plan) | 99,716 | $63.26 | $6.3M | Form 4 | |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Sell (10b5-1 plan) | 96,125 | $63.64 | $6.1M | Form 4 | |
| William E. Rote | Chief Research Officer | Option exercise | 39,000 | $25.25 | $985K | Form 4 | |
| William E. Rote | Chief Research Officer | Option exercise | 39,650 | $17.96 | $712K | Form 4 | |
| William E. Rote | Chief Research Officer | Sell (10b5-1 plan) | 63,907 | $61.99 | $4M | Form 4 | |
| William E. Rote | Chief Research Officer | Sell (10b5-1 plan) | 29,021 | $62.66 | $1.8M | Form 4 | |
| William E. Rote | Chief Research Officer | Sell (10b5-1 plan) | 3,000 | $63.65 | $191K | Form 4 | |
| William E. Rote | Chief Research Officer | Sell (10b5-1 plan) | 270 | $65.31 | $18K | Form 4 | |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Option exercise | 39,283 | $26.88 | $1.1M | Form 4 | |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Option exercise | 1,381 | $22.40 | $31K | Form 4 | |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Option exercise | 36,526 | $8.93 | $326K | Form 4 | |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Sell (10b5-1 plan) | 71,938 | $62.05 | $4.5M | Form 4 | |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Sell (10b5-1 plan) | 27,421 | $62.59 | $1.7M | Form 4 | |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Sell (10b5-1 plan) | 1,400 | $63.65 | $89K | Form 4 | |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Sell (10b5-1 plan) | 1,431 | $65.31 | $93K | Form 4 | |
| Jula Inrig | EVP, Head of R&D & CMO | Option exercise | 32,395 | $8.93 | $289K | Form 4 | |
| Jula Inrig | EVP, Head of R&D & CMO | Sell (10b5-1 plan) | 25,390 | $62.02 | $1.6M | Form 4 | |
| Jula Inrig | EVP, Head of R&D & CMO | Sell (10b5-1 plan) | 17,284 | $62.62 | $1.1M | Form 4 | |
| Jula Inrig | EVP, Head of R&D & CMO | Sell (10b5-1 plan) | 1,600 | $63.69 | $102K | Form 4 | |
| Jula Inrig | EVP, Head of R&D & CMO | Sell (10b5-1 plan) | 400 | $65.31 | $26K | Form 4 | |
| Elizabeth E Reed | Chief Legal Officer and GC | Option exercise | 37,500 | $15.46 | $580K | Form 4 | |
| Elizabeth E Reed | Chief Legal Officer and GC | Sell (10b5-1 plan) | 21,926 | $62.03 | $1.4M | Form 4 | |
| Elizabeth E Reed | Chief Legal Officer and GC | Sell (10b5-1 plan) | 13,874 | $62.63 | $869K | Form 4 | |
| Elizabeth E Reed | Chief Legal Officer and GC | Sell (10b5-1 plan) | 1,400 | $63.69 | $89K | Form 4 | |
| Elizabeth E Reed | Chief Legal Officer and GC | Sell (10b5-1 plan) | 300 | $65.31 | $20K | Form 4 | |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Option exercise | 95,666 | $23.34 | $2.2M | Form 4 | |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Sell (10b5-1 plan) | 63,498 | $61.99 | $3.9M | Form 4 | |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Sell (10b5-1 plan) | 28,796 | $62.66 | $1.8M | Form 4 | |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Sell (10b5-1 plan) | 3,102 | $63.64 | $197K | Form 4 | |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Sell (10b5-1 plan) | 270 | $65.31 | $18K | Form 4 | |
| Christopher R. Cline | CHIEF FINANCIAL OFFICER | Option exercise | 20,000 | $17.44 | $349K | Form 4 | |
| Christopher R. Cline | CHIEF FINANCIAL OFFICER | Sell (10b5-1 plan) | 27,473 | $62.00 | $1.7M | Form 4 | |
| Christopher R. Cline | CHIEF FINANCIAL OFFICER | Sell (10b5-1 plan) | 20,735 | $62.61 | $1.3M | Form 4 | |
| Christopher R. Cline | CHIEF FINANCIAL OFFICER | Sell (10b5-1 plan) | 1,900 | $63.69 | $121K | Form 4 | |
| Christopher R. Cline | CHIEF FINANCIAL OFFICER | Sell (10b5-1 plan) | 400 | $65.31 | $26K | Form 4 | |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Option exercise | 2,500 | $27.50 | $69K | Form 4 | |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Option exercise | 1,250 | $22.40 | $28K | Form 4 | |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Option exercise | 1,625 | $20.46 | $33K | Form 4 | |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sell (10b5-1 plan) | 4,275 | $62.14 | $266K | Form 4 | |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sell (10b5-1 plan) | 800 | $62.85 | $50K | Form 4 | |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sell (10b5-1 plan) | 300 | $63.66 | $19K | Form 4 | |
| Jeffrey A Meckler | Director | Option exercise | 10,000 | $17.44 | $174K | Form 4 | |
| Jeffrey A Meckler | Director | Option exercise | 10,000 | $26.52 | $265K | Form 4 | |
| Jeffrey A Meckler | Director | Sell (10b5-1 plan) | 1,700 | $65.39 | $111K | Form 4 | |
| Jeffrey A Meckler | Director | Sell (10b5-1 plan) | 1,200 | $66.15 | $79K | Form 4 | |
| Jeffrey A Meckler | Director | Sell (10b5-1 plan) | 14,000 | $67.46 | $944K | Form 4 | |
| Jeffrey A Meckler | Director | Sell (10b5-1 plan) | 3,100 | $68.09 | $211K | Form 4 | |
| Christopher R. Cline | CHIEF FINANCIAL OFFICER | Sell | 642 | $66.37 | $43K | Form 4 | |
| Gary A Lyons | Director | Option exercise | 5,000 | $17.44 | $87K | Form 4 | |
| Gary A Lyons | Director | Sell (10b5-1 plan) | 4,100 | $63.27 | $259K | Form 4 | |
| Gary A Lyons | Director | Sell (10b5-1 plan) | 900 | $63.86 | $57K | Form 4 | |
| Gary A Lyons | Director | Option exercise | 5,000 | $17.44 | $87K | Form 4 | |
| Gary A Lyons | Director | Sell (10b5-1 plan) | 1,900 | $62.53 | $119K | Form 4 | |
| Gary A Lyons | Director | Sell (10b5-1 plan) | 2,600 | $63.50 | $165K | Form 4 | |
| Gary A Lyons | Director | Sell (10b5-1 plan) | 500 | $64.16 | $32K | Form 4 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.